US 10544228

Patent Overview — US10544228B2

Title: Nucleic acids encoding antibody polypeptides that antagonize CD40

Source: https://patents.google.com/patent/[US10544228](/patent/US10544228)/en

Bibliographic data (as shown in the excerpt): Patent number US10544228B2; application US15/259,828; filed 2016-09-08; granted 2020-01-28; priority date 2011-04-21; adjusted expiration 2034-10-02; status listed as Active. Current assignees listed as Domantis Ltd and Bristol Myers Squibb Co. Inventors listed: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew. A prior-art keyword listing includes "bms3h," "antibody," "amino acid," "variable domain," and "seq." Classifications place it in C07K16/2878 (antibodies against NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95), with additional A61K and A61P therapeutic classifications.

Purpose: The title states the subject matter is nucleic acids encoding antibody polypeptides that antagonize CD40 — i.e., the claimed nucleic acids encode antibody polypeptides characterized by CD40-antagonist activity.

Plain-language scope (as far as the excerpt shows): Based only on the supplied text, the patent concerns nucleic acid molecules that encode antibody polypeptides capable of antagonizing CD40, an immune cell surface receptor. The classification and litigation/homepage metadata do not themselves define claim scope.

What the excerpt does not establish:

• The actual wording of any claim, and therefore the precise metes and bounds of the monopoly.
• The specific nucleotide or amino acid sequences (SEQ ID NOs) covered, antibody formats, CDR sequences, or CD40-binding properties.
• Whether, or how, the nucleic acids are used in expression systems, vectors, host cells, pharmaceutical compositions, or treatment methods.
• The identity of any prior art or the basis of patentability.
• The completeness of the specification, figures, or claims, which are not reproduced here.

The excerpt contains bibliographic and classification metadata and images only; the substantive description and claims are omitted. No litigation status, ownership history, validity, or prior-art conclusions are drawn here.